March 2025 in “Scientific Reports” This study evaluated a menthol-based microemulsion for transdermal delivery of finasteride and silodosin, finding that it enhanced skin permeation and flux compared to aqueous solutions, suggesting a promising method for managing benign prostatic hyperplasia.
June 2024 in “International Journal of Pharmaceutical Quality Assurance” This study established a new reverse-phase high-performance liquid chromatography method to accurately and precisely quantify silodosin and dutasteride in mixtures, meeting International Council of Harmonization validation criteria for stability, sensitivity, and recovery.
15 citations
,
November 2015 in “Pharmacopsychiatry” This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.
6 citations
,
July 2021 in “Uro” This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.
August 2025 in “The Journal of Sexual Medicine” This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.